Precision Historical Balance Sheet
DTIL Stock | USD 7.11 0.25 3.64% |
Trend analysis of Precision BioSciences balance sheet accounts such as Total Current Liabilities of 34 M or Total Stockholder Equity of 17.9 M provides information on Precision BioSciences' total assets, liabilities, and equity, which is the actual value of Precision BioSciences to its prevalent stockholders. By breaking down trends over time using Precision BioSciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Precision BioSciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Precision BioSciences is a good buy for the upcoming year.
Precision BioSciences Inventory |
|
Precision |
About Precision Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Precision BioSciences at a specified time, usually calculated after every quarter, six months, or one year. Precision BioSciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Precision BioSciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Precision currently owns. An asset can also be divided into two categories, current and non-current.
Precision BioSciences Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Precision BioSciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Precision BioSciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Precision BioSciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Precision BioSciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most accounts from Precision BioSciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Precision BioSciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.At this time, Precision BioSciences' Total Current Assets are quite stable compared to the past year. Property Plant Equipment is expected to rise to about 25 M this year, although the value of Total Current Liabilities will most likely fall to about 34 M.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 9.9M | 11.1M | 11.4M | 6.7M | Total Assets | 211.5M | 238.2M | 159.8M | 179.4M |
Precision BioSciences balance sheet Correlations
Click cells to compare fundamentals
Precision BioSciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Precision BioSciences balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 235.2M | 150.2M | 211.5M | 238.2M | 159.8M | 179.4M | |
Other Current Liab | 1.6M | 7.9M | 9.9M | 11.1M | 11.4M | 6.7M | |
Total Current Liabilities | 26.9M | 42.8M | 36.0M | 59.7M | 50.0M | 34.0M | |
Total Stockholder Equity | 138.3M | 44.4M | 91.2M | 60.4M | 18.9M | 17.9M | |
Other Liab | 70.0M | 54.3M | 77.1M | 93.1M | 83.8M | 64.4M | |
Net Tangible Assets | 136.9M | 43.1M | 89.1M | 59.1M | 67.9M | 52.7M | |
Retained Earnings | (177.1M) | (286.1M) | (316.7M) | (428.3M) | (489.6M) | (465.1M) | |
Accounts Payable | 2.0M | 792K | 1.1M | 653K | 3.0M | 1.8M | |
Cash | 180.9M | 89.8M | 143.7M | 189.6M | 116.7M | 134.8M | |
Other Assets | 558K | 8.1M | 11.5M | 9.8M | 1.0 | 0.95 | |
Cash And Short Term Investments | 180.9M | 89.8M | 143.7M | 189.6M | 116.7M | 134.8M | |
Net Receivables | 965K | 10M | 488K | 720K | 12.8M | 13.4M | |
Common Stock Shares Outstanding | 1.4M | 1.7M | 2.0M | 2.9M | 3.8M | 3.1M | |
Capital Surpluse | 316.3M | 331.5M | 408.8M | 489.7M | 563.2M | 591.3M | |
Total Liab | 96.9M | 105.7M | 120.3M | 177.7M | 140.9M | 129.6M | |
Total Current Assets | 193.7M | 105.6M | 161.8M | 199.1M | 136.4M | 147.2M | |
Intangible Assets | 1.4M | 1.4M | 2.0M | 1.3M | 400K | 380K | |
Property Plant Equipment | 39.6M | 41.5M | 25.2M | 20.2M | 23.2M | 25.0M | |
Property Plant And Equipment Net | 39.6M | 41.5M | 29.3M | 23.2M | 14.6M | 27.9M | |
Current Deferred Revenue | 16.5M | 30.2M | 21.2M | 46.2M | 12.0M | 22.1M | |
Net Debt | (180.9M) | (79.3M) | (134.6M) | (162.5M) | (85.4M) | (89.7M) | |
Non Current Assets Total | 41.6M | 44.6M | 49.7M | 39.1M | 23.4M | 36.1M | |
Non Currrent Assets Other | 558K | 1.7M | 4.6M | 9.8M | 225K | 213.8K | |
Liabilities And Stockholders Equity | 235.2M | 150.2M | 211.5M | 238.2M | 159.8M | 189.5M | |
Non Current Liabilities Total | 70.0M | 62.9M | 84.4M | 118.1M | 90.9M | 94.4M | |
Other Current Assets | 2.3M | 5.8M | 17.6M | 8.8M | 6.9M | 8.5M | |
Other Stockholder Equity | 315.4M | 330.5M | 407.8M | 488.7M | 508.5M | 345.3M | |
Net Invested Capital | 138.3M | 44.4M | 93.6M | 82.7M | 41.3M | 65.0M | |
Property Plant And Equipment Gross | 39.6M | 41.5M | 53.2M | 54.3M | 40.1M | 40.5M | |
Net Working Capital | 166.7M | 62.7M | 125.8M | 139.4M | 86.4M | 115.9M | |
Short Term Debt | 6.8M | 3.9M | 3.6M | 1.7M | 23.5M | 24.7M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.4 | Revenue Per Share 12.872 | Quarterly Revenue Growth (0.96) | Return On Assets (0.06) | Return On Equity 0.2444 |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.